同侧锁骨上淋巴结转移对N3期乳腺癌预后的影响分析
该回顾性研究纳入321例N3期乳腺癌患者,用倾向评分匹配比较有无同侧锁骨上淋巴结转移者的预后,发现两组无病生存与总生存差异均无统计学意义,支持AJCC第6版将锁骨上淋巴结转移归入N3期的合理性。
要点
- 有无锁骨上淋巴结转移的N3期乳腺癌患者DFS与OS差异无统计学意义。
- 倾向评分匹配后两组中位DFS与OS数值互有长短,P值均未达显著。
- 结果支持AJCC第6版将同侧锁骨上淋巴结转移划入N3期。
核心结论
- 同侧锁骨上淋巴结转移与无锁骨上淋巴结转移的N3期乳腺癌患者预后相似,将其划入N3期具有合理性。
研究设计与样本
- 回顾性分析初诊淋巴结分期为N3期的321例乳腺癌患者的临床病理资料。
- 采用倾向评分匹配对不同部位淋巴结转移的N3期患者进行匹配分组。
- 主要终点为无病生存时间(DFS),次要终点为总生存时间(OS),生存分析采用Kaplan-Meier法和Log-rank检验。
主要发现
- 第1次匹配腋窝组与锁骨上±腋窝组各78例,中位DFS分别为58.9个月和32.1个月(P=0.101)。
- 第1次匹配腋窝组与锁骨上±腋窝组中位OS分别为87.4个月和140.4个月(P=0.277)。
- 第2次匹配腋窝组与仅锁骨上组各51例,中位DFS分别为59.0个月和44.0个月(P=0.533)。
- 第2次匹配腋窝组与仅锁骨上组中位OS分别为87.4个月和137.1个月(P=0.289)。
临床怎么用
- 对N3期乳腺癌伴同侧锁骨上淋巴结转移者,可按N3期而非M1期考虑根治性治疗策略。
- 预后判断时应结合淋巴结转移部位综合评估,而非仅凭锁骨上淋巴结转移即判定为晚期。
局限性
- 本研究为单中心回顾性分析,样本量有限。
- 结论尚需更大样本量的前瞻性研究进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The 6th edition American Joint Committee on Cancer (AJCC) staging system for breast cancer classifies ipsilateral supraclavicular lymph node metastasis (ISLM) downing stage from M1 to N3, suggesting more patients might receive radical treatment. The aim of this study was to analyze the effect of ISLM on the prognosis of N3 breast cancer and verify the rationality of modified staging. Methods: A total of 321 breast cancer patients with N3 according to the 6th edition AJCC staging system were retrospectively analyzed. Propensity Score Matching (PSM) was used to pair the different subgroups of N3. The primary end point was disease-free survival (DFS), the secondary end point was overall survival (OS). Kaplan-Meier method was used to calculate the DFS and OS. The differences between two groups were analyzed by the Log-rank test. Results: After PSM pairing twice, 78 patients with none-ISLM and 78 patients with ISLM were enrolled in the first group; 51 patients with none-ISLM was compared patients with isolated ISLM in the second group. The results of the two groups showed that patients with none-ISLM have a prolonged DFS (the first group: 58.9 months vs 32.1 months, P=0.101; the second group: 59.0 months vs 44.0 months, P=0.533), while the OS was opposite (the first group: 87.4 months vs 140.4 months, P=0.289; the second group: 87.4 months vs 137.1 months, P=0.289). Conclusions: The prognosis of breast cancer patients with ISLM is similar to that of patients with none-ISLM in stage N3. It is reasonable to include ISLM in N3 in the 6th edition AJCC staging system. Yet, prospective studies with larger sample size are needed to further confirmation. 目的: 探讨同侧锁骨上淋巴结转移对N3期乳腺癌预后的影响以及美国癌症联合委员会(AJCC)第6版乳腺癌分期的合理性。 方法: 回顾性分析初诊淋巴结分期为N3期的321例乳腺癌患者的临床病理资料,通过倾向评分匹配(PSM)对不同部位淋巴结转移的N3期患者进行匹配分组,主要研究终点为无病生存时间(DFS),次要研究终点为总生存时间(OS)。生存分析采用Kaplan-Meier法和Log rank检验。 结果: 应用PSM法进行2次匹配,第1次匹配无锁骨上淋巴结转移(腋窝组)和含锁骨上淋巴结转移(锁骨上±腋窝组)的N3期乳腺癌各78例,腋窝组和锁骨上±腋窝组患者的中位DFS分别为58.9和32.1个月(P=0.101),中位OS分别为87.4和140.4个月(P=0.277)。第2次匹配腋窝组和仅锁骨上淋巴结转移锁骨上组的N3期乳腺癌患者各51例,腋窝组和锁骨上组患者的中位DFS分别为59.0和44.0个月(P=0.533),中位OS分别为87.4和137.1个月(P=0.289)。 结论: 乳腺癌同侧锁骨上淋巴结转移与无锁骨上淋巴结转移N3期患者的预后相似,AJCC第6版乳腺癌TNM分期将其划入淋巴结转移N3期具有合理性。.
引用
- Nilupai A, Wang JY, Li Q, et al. [Analysis of the effect of ipsilateral supraclavicular lymph node metastasis on the prognosis of N3 breast cancer]. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34695897. doi:10.3760/cma.j.cn112152-20191227-00845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。